Zhongzhi Pharmaceutical Holdings Limited(HK:3737)
HK$0.66+0.01 (+0.77%)
HK:3737
Zhongzhi Pharmaceutical Holdings Limited financials statements
HK$0.66
At close:+0.01 (+0.77%)
Want to see HK:3737 full AI Analyst Report?
Zhongzhi Pharmaceutical Holdings Limited (3737) Ratios
0 Followers
Zhongzhi Pharmaceutical Holdings Limited Ratios
HK:3737's free cash flow for Q2 2026 was ¥121.23M. For the 2026 fiscal year, HK:3737's free cash flow was decreased by ¥-15.33M and operating cash flow was ¥136.56M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.60 | 1.39 | 1.44 | 1.49 | 1.71 |
| Quick Ratio | 1.15 | 0.91 | 0.89 | 1.05 | 1.18 |
| Cash Ratio | 0.32 | 0.23 | 0.27 | 0.52 | 0.47 |
| Solvency Ratio | 0.16 | 0.17 | 0.36 | 0.18 | 0.15 |
| Operating Cash Flow Ratio | 0.17 | 0.25 | 0.17 | 0.39 | 0.36 |
| Short-Term Operating Cash Flow Coverage | 0.67 | 3.92 | 1.31 | 7.90 | 3.12 |
| Net Current Asset Value | ¥ 263.77M | ¥ 148.54M | ¥ 134.82M | ¥ 221.61M | ¥ 234.50M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.12 | 0.09 | 0.13 | 0.09 | 0.12 |
| Debt-to-Equity Ratio | 0.21 | 0.17 | 0.21 | 0.17 | 0.20 |
| Debt-to-Capital Ratio | 0.17 | 0.14 | 0.18 | 0.15 | 0.16 |
| Long-Term Debt-to-Capital Ratio | 0.03 | 0.03 | 0.02 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.67 | 1.78 | 1.71 | 1.87 | 1.70 |
| Debt Service Coverage Ratio | 0.61 | 2.24 | 3.21 | 3.06 | 1.71 |
| Interest Coverage Ratio | 0.94 | 18.57 | 21.58 | 16.24 | 12.06 |
| Debt to Market Cap | 0.46 | 0.11 | 0.09 | 0.04 | 0.08 |
| Interest Debt Per Share | 0.28 | 0.23 | 0.27 | 0.21 | 0.22 |
| Net Debt to EBITDA | 0.26 | 0.13 | 0.19 | -1.37 | -0.48 |
| Profitability Margins | |||||
| Gross Profit Margin | 54.12% | 58.17% | 59.43% | 58.45% | 60.77% |
| EBIT Margin | -0.10% | 5.39% | 10.51% | 5.67% | 4.56% |
| EBITDA Margin | 5.74% | 7.69% | 15.49% | 8.43% | 6.85% |
| Operating Profit Margin | 0.28% | 5.86% | 8.28% | 5.83% | 4.89% |
| Pretax Profit Margin | 1.09% | 6.63% | 10.13% | 7.16% | 3.54% |
| Net Profit Margin | 1.00% | 4.30% | 7.94% | 5.83% | 2.98% |
| Continuous Operations Profit Margin | 1.02% | 4.34% | 8.01% | 5.86% | 3.00% |
| Net Income Per EBT | 91.06% | 64.82% | 78.42% | 81.43% | 84.33% |
| EBT Per EBIT | 385.21% | 113.13% | 122.24% | 122.76% | 72.40% |
| Return on Assets (ROA) | 0.94% | 4.79% | 9.08% | 5.67% | 3.42% |
| Return on Equity (ROE) | 1.58% | 8.53% | 15.52% | 10.61% | 5.80% |
| Return on Capital Employed (ROCE) | 0.41% | 10.34% | 14.34% | 9.30% | 8.34% |
| Return on Invested Capital (ROIC) | 0.34% | 6.35% | 10.25% | 8.34% | 6.98% |
| Return on Tangible Assets | 0.95% | 4.82% | 9.16% | 5.73% | 3.47% |
| Earnings Yield | 4.17% | 12.11% | 14.77% | 13.05% | 7.72% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.93 | 5.04 | 6.25 | 5.86 | 5.95 |
| Payables Turnover | 4.84 | 4.39 | 4.87 | 4.20 | 4.63 |
| Inventory Turnover | 2.84 | 2.68 | 2.52 | 2.35 | 2.56 |
| Fixed Asset Turnover | 2.58 | 3.03 | 3.09 | 3.18 | 3.19 |
| Asset Turnover | 0.95 | 1.11 | 1.14 | 0.97 | 1.15 |
| Working Capital Turnover Ratio | 5.29 | 8.08 | 6.56 | 5.10 | 4.63 |
| Cash Conversion Cycle | 145.93 | 125.37 | 128.31 | 130.80 | 125.39 |
| Days of Sales Outstanding | 92.84 | 72.44 | 58.40 | 62.28 | 61.35 |
| Days of Inventory Outstanding | 128.52 | 136.07 | 144.84 | 155.37 | 142.80 |
| Days of Payables Outstanding | 75.43 | 83.15 | 74.93 | 86.85 | 78.77 |
| Operating Cycle | 221.36 | 208.51 | 203.24 | 217.65 | 204.15 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.13 | 0.21 | 0.12 | 0.34 | 0.21 |
| Free Cash Flow Per Share | 0.08 | 0.05 | -0.08 | 0.23 | -0.01 |
| Dividend Paid and CapEx Coverage Ratio | 1.45 | 1.10 | 0.35 | 3.21 | 0.96 |
| Capital Expenditure Coverage Ratio | 3.04 | 1.28 | 0.59 | 3.22 | 0.96 |
| Operating Cash Flow Coverage Ratio | 0.46 | 0.96 | 0.45 | 1.67 | 1.02 |
| Operating Cash Flow to Sales Ratio | 0.06 | 0.08 | 0.05 | 0.16 | 0.10 |
| Free Cash Flow Yield | 16.87% | 5.04% | -6.34% | 24.06% | -1.11% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 24.54 | 8.26 | 6.77 | 7.66 | 12.95 |
| Price-to-Sales (P/S) Ratio | 0.24 | 0.35 | 0.54 | 0.45 | 0.39 |
| Price-to-Book (P/B) Ratio | 0.38 | 0.70 | 1.05 | 0.81 | 0.75 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 5.93 | 19.84 | -15.76 | 4.16 | -90.33 |
| Price-to-Operating Cash Flow Ratio | 3.98 | 4.33 | 10.86 | 2.86 | 3.78 |
| Price-to-Earnings Growth (PEG) Ratio | -0.30 | -0.20 | 0.15 | 0.07 | -0.20 |
| Enterprise Value Multiple | 4.41 | 4.74 | 3.66 | 3.93 | 5.16 |
| Enterprise Value | 440.32M | 807.59M | 1.16B | 605.06M | 617.16M |
| EV to EBITDA | 4.41 | 4.74 | 3.66 | 3.93 | 5.16 |
| EV to Sales | 0.25 | 0.36 | 0.57 | 0.33 | 0.35 |
| EV to Free Cash Flow | 6.30 | 20.38 | -16.63 | 3.08 | -82.62 |
| EV to Operating Cash Flow | 4.23 | 4.45 | 11.46 | 2.13 | 3.46 |
| Tangible Book Value Per Share | 1.32 | 1.31 | 1.21 | 1.17 | 1.05 |
| Shareholders’ Equity Per Share | 1.33 | 1.32 | 1.22 | 1.18 | 1.07 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.07 | 0.35 | 0.21 | 0.18 | 0.15 |
| Revenue Per Share | 2.11 | 2.62 | 2.39 | 2.16 | 2.09 |
| Net Income Per Share | 0.02 | 0.11 | 0.19 | 0.13 | 0.06 |
| Tax Burden | 0.91 | 0.65 | 0.78 | 0.81 | 0.84 |
| Interest Burden | -11.35 | 1.23 | 0.96 | 1.26 | 0.78 |
| Research & Development to Revenue | 0.02 | 0.03 | 0.02 | 0.03 | 0.03 |
| SG&A to Revenue | 0.51 | 0.49 | 0.05 | 0.06 | 0.06 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 6.19 | 1.24 | 0.49 | 2.67 | 3.42 |
Currency in CNY
